These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17020686)

  • 61. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recombinant erythropoietin therapy in renal and nonrenal anemia.
    Erslev AJ
    West J Med; 1992 Aug; 157(2):195-6. PubMed ID: 1441490
    [No Abstract]   [Full Text] [Related]  

  • 63. Drug distribution and expenditure: the issue of epoetin in Italy.
    La Vecchia C; Franceschi S; Apolone G
    Eur J Public Health; 2003 Dec; 13(4):367. PubMed ID: 14703326
    [No Abstract]   [Full Text] [Related]  

  • 64. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
    Eschbach JW; Haley NR; Adamson JW
    Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
    [No Abstract]   [Full Text] [Related]  

  • 65. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy.
    Goicoechea M; Gomez-Campdera F; Polo JR; Tejedor A; Ruiz MA; Vazquez I; Verde E; Valderrabano F
    Clin Nephrol; 1996 Jun; 45(6):420-1. PubMed ID: 8793241
    [No Abstract]   [Full Text] [Related]  

  • 66. Influence of rhEPO therapy on the protein metabolism of hemodialysis patients with terminal renal insufficiency.
    Fischer C; Scigalla P; Park W; Becker H; Schiller R; Paust H; Broesicke H; Kessel M
    Contrib Nephrol; 1989; 76():250-6. PubMed ID: 2684526
    [No Abstract]   [Full Text] [Related]  

  • 67. Anemia management in patients with chronic renal insufficiency.
    Kausz AT; Obrador GT; Pereira BJ
    Am J Kidney Dis; 2000 Dec; 36(6 Suppl 3):S39-51. PubMed ID: 11118157
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end point?
    Covic A; Seica A; Gusbeth-Tatomir P; Goldsmith D
    J Nephrol; 2008; 21(4):478-84. PubMed ID: 18651536
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Erythropoietin and chronic renal failure.
    Drüeke T; Zins B; Naret C; Casadevall N; Goureau Y; Bererhi L; Zingraff J; Delons S; Kreis H; Varet B
    Nouv Rev Fr Hematol (1978); 1989; 31(2):97-8. PubMed ID: 2771635
    [No Abstract]   [Full Text] [Related]  

  • 70. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously.
    Macdougall IC; Hutton RD; Cavill I; Coles GA; Williams JD
    BMJ; 1989 Jul; 299(6692):157-8. PubMed ID: 2504356
    [No Abstract]   [Full Text] [Related]  

  • 71. Erythropoietin use in pregnancy: two cases and a review of the literature.
    Scott LL; Ramin SM; Richey M; Hanson J; Gilstrap LC
    Am J Perinatol; 1995 Jan; 12(1):22-4. PubMed ID: 7710570
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recombinant human erythropoietin and peritoneal dialysis.
    Digenis GE; Yatzidis H
    Int J Artif Organs; 1990 Jun; 13(6):344-6. PubMed ID: 2199378
    [No Abstract]   [Full Text] [Related]  

  • 73. Erythropoietin, an update, and where to in the future?
    Sulková S
    EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron.
    Silverberg DS; Wexler D; Blum M; Tchebiner JZ; Sheps D; Keren G; Schwartz D; Baruch R; Yachnin T; Shaked M; Schwartz I; Steinbruch S; Iaina A
    Nephrol Dial Transplant; 2003 Jan; 18(1):141-6. PubMed ID: 12480972
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correction of anemia by recombinant human erythropoietin in a patient with polycythemia vera associated with hemodialysis-dependent chronic renal failure.
    Ohyashiki JH; Fujieda H; Ohyashiki K; Toyama K
    Am J Hematol; 1991 Jun; 37(2):141-2. PubMed ID: 2069164
    [No Abstract]   [Full Text] [Related]  

  • 76. Implications of recombinant erythropoietin therapy for renal transplantation.
    Ward HJ
    Am J Nephrol; 1990; 10 Suppl 2():44-7; discussion 48-52. PubMed ID: 2260618
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 78. Safety and efficiency of recombinant human erythropoietin treatment in anemic pregnant women with a kidney transplant.
    Szurkowski M; Wiecek A; Kokot F; Daniel K
    Nephron; 1994; 67(2):242-3. PubMed ID: 8072619
    [No Abstract]   [Full Text] [Related]  

  • 79. Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.
    Winearls CG
    Drugs; 1989 Sep; 38(3):342-5. PubMed ID: 2806134
    [No Abstract]   [Full Text] [Related]  

  • 80. Treatment of anaemia resistant to conventional erythropoietin therapy with thymopentin in haemodialysis patients.
    Raiola P; Manzo M; Saggese A; Tomasino G; Cicchella T; Rambaldi M; Pisano M; Lizza B; Perna AF
    Nephrol Dial Transplant; 1995; 10 Suppl 6():48-50. PubMed ID: 8524495
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.